Englander Institute for Precision Medicine

Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer.

TitleAnti-EGFR Antibodies in the Management of Advanced Colorectal Cancer.
Publication TypeJournal Article
Year of Publication2023
AuthorsKasi PMurtaza, Afable MGeroy, Herting C, Lukanowski M, Jin Z
Date Published2023 Dec 11
KeywordsAntibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Cetuximab, Colorectal Neoplasms, ErbB Receptors, Humans

Colorectal cancer is the third most common cancer worldwide, and incidence is rising in younger individuals. Anti-EGFR antibodies, including cetuximab and panitumumab, have been incorporated into standard-of-care practice for patients with advanced disease. Herein, we review the molecular characteristics of these agents and the trials that lead to their approvals. Further, we discuss clinical implications of data regarding biomarkers that dictate treatment selection, different dosing strategies, and side effect management. Finally, we look towards the future and describe contexts in which these agents are currently being investigated clinically with a focus on combinations with MAPK-targeted therapies and immunotherapy. Overall, this review provides historical context, current clinical usage, and future directions for anti-EGFR antibodies in advanced colorectal cancer.

Alternate JournalOncologist
PubMed ID37774394
Grant List / / Eli Lilly and Company /

Weill Cornell Medicine Englander Institute for Precision Medicine 413 E 69th Street
Belfer Research Building
New York, NY 10021